1. India Stocks

  2. •

    Process industries

  3. •

    Chemicals: specialty
Samrat Pharmachem Limited

Samrat Pharmachem Limited

BBSE:SAMRATPH
288.10
INR
+15.95
(+5.86%)
-7.15EPS
678.65MMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
209.86
152.81
200.2
230.04
299.19
359.61
444.71
579.27
717.71
1,005.42
911.35
925.2
937.7
951.72
Basic EPS, GAAP
0.78
1.02
0.98
5.68
10.41
4.97
13.71
17.26
55.62
53.83
7
23.02
-10.72
-7.15
Free Cash Flow per Basic Share
10.72
-2.36
-2.85
-12.48
-0.17
6.72
-10.25
6.7
52.42
-35.27
28.3
-34.3
18.72
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
- -
Book Value per Share
42.52
43.55
43.89
49.57
59.98
64.95
78.66
95.92
151.54
204.37
210.37
232.39
220.67
- -
Tangible Book Value per Share
42.45
43.49
43.7
49.42
59.89
64.91
78.65
95.89
151.51
204.34
210.35
232.34
220.63
- -
Basic Weighted Avg Shares
3
3
3
3
3
3
3
3
3
3
3
3
3
3
Sales/Revenue/Turnover
648
473
619
711
924
1,111
1,374
1,790
2,218
3,106
2,816
2,859
2,897
2,938
Operating Margin (%)
1.46
1.8
1.22
4.7
5.92
2.64
4.53
4.88
10.72
7.53
0.66
3.41
-0.96
-0.72
Depreciation Expense
3
4
4
4
4
4
4
5
6
6
6
7
7
7
Net Income, GAAP
2
3
3
18
32
15
42
53
172
166
22
71
-33
-22
Effective Tax Rate (%)
40.65
34.04
32.85
36.79
34.62
28.83
26.76
27.38
27.19
26.19
14.19
28.06
- -
- -
Profit Margin (%)
0.37
0.67
0.49
2.47
3.48
1.38
3.08
2.98
7.75
5.35
0.77
2.49
-1.14
-0.75
Working Capital
63
64
79
92
122
134
158
200
339
459
462
538
480
- -
LT Debt
7
3
15
12
8
3
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
131
135
136
153
185
201
243
296
468
631
650
718
682
- -
Return on Invested Capital (%)
1.44
1.92
1.68
7.51
13.63
7.44
15.17
17.11
34.86
23.52
2.03
8.85
- -
- -
Return on Capital (%)
2.52
2.93
2.65
9.84
14.35
7.64
15.82
16.67
37.62
25.44
3.4
9.62
- -
- -
Return on Common Equity (%)
1.86
2.38
2.23
12.15
19.01
7.96
19.1
19.77
44.95
30.25
3.38
10.4
-4.73
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
107
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3
3
3
Market Capitalization
702
602
679

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
1,038
- -
Cash, Cash Equivalents & STI
- -
63
- -
Accounts Receivable, Net
- -
510
- -
Inventories
- -
436
- -
Total Current Liabilities
- -
558
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
107
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
18.65%
20.24%
-5.04%
Free Cash Flow
-418.81%
-8.08%
-154.57%
Net Income, GAAP
92.94%
42.86%
-146.57%
Sales/Revenue/Turnover
17.66%
11.5%
1.35%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
808
702
637
712
2,859
2026
757
789
634
718
2,897
2027
798
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
6.69
8.61
9.01
-1.29
23.02
2026
-0.74
-1.9
-1.49
-6.59
-10.72
2027
2.84
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
1
2026
- -
- -
- -
- -
1
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Lalit Damodar Mehta
Full Time Employees
30
Sector
Process industries
Industry
Chemicals: specialty
Address
701 Mumbai MA India 400058
IPO Date
Feb 28, 1995
Website
samratpharmachem.com
Similar Companies
Petkim Petrokimya Holding Anonim Sirketi (BIST:PETKM)
Albemarle Corporation (NYSE:ALB)
Linde plc (NASDAQ:LIN)
Gubre Fabrikalari T.A.S. (BIST:GUBRF)
IOL Chemicals & Pharmaceuticals Ltd. (NSE:IOLCP)
PI Industries Limited (NSE:PIIND)
Business
Samrat Pharmachem Limited manufactures and exports a broad range of iodine and bromine derivatives from its facilities in Ankleshwar, Gujarat, India, where it was incorporated in 1992 and listed on the Bombay Stock Exchange in 1995; the company maintains its corporate office in Mumbai. Its core products include 3-5 diiodosalicylic acid, ammonium iodide, cadmium iodide, calcium iodate, clioquinol, copper iodide, ethyl iodide, ethylenediamine dihydroiodide, hydroiodic acid, iodic acid, iodine monochloride, iodoquinol, lithium iodide, methyl iodide, N-iodosuccinimide, periodic acid, potassium iodate, potassium iodide, potassium metaperiodate, povidone iodine, selenium dioxide, sodium iodate, sodium iodide, sodium metaperiodate, sodium selenite, and trimethyl sulphoxonium iodide, serving industries such as pharmaceuticals, agrochemicals, animal nutrition, chemicals, cosmetics, food, fertilizers, salt, textiles, and tire cord manufacturing. The company exports to the United States, Europe, Africa, Asia, the Middle East, and other international markets, supplying multinational customers with facilities approved by regulators including USFDA, EU GMP, UK MHRA, Health Canada, WHO, and Brazil ANVISA. Recent developments include obtaining Authorized Economic Operator certification from Indian Customs and applying for USFDA plant approval in 2021, receiving additional production consent and expanding production lines from GPCB in 2019, earning ISO, FAMI-QS, and government-recognized Export House accreditations in 2017, alongside ongoing R&D enhancements and GMP compliance upgrades.